Literature DB >> 15195124

PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.

J-P Meyer1, D A Gillatt.   

Abstract

In this review the authors consider the commercially available herbal product PC-SPES. This is a combination of eight different herbs marketed for its effects of reducing prostate specific antigen (PSA) levels, improving pain, and enhancing the quality of life of those with hormone refractory prostate cancer. The evidence for these claims does not appear to be as conclusive as reported by the manufactures of this product. There also appears to be a significant risk of deep vein thrombosis (DVT) in those treated with PC-SPES. There have been 116 clinical and laboratory based studies of PC-SPES published to date, but there have been no randomised controlled trials conducted. Many of these studies contain very few patients, thus making the drawing of conclusions difficult. Despite this lack of information, there still remains a large patient group taking this supplement, therefore caution should be advised in the usage of PC-SPES in the treatment of hormone refractory prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15195124     DOI: 10.1038/sj.pcan.4500563

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  3 in total

Review 1.  Safety surveillance of traditional Chinese medicine: current and future.

Authors:  Shwu-Huey Liu; Wu-Chang Chuang; Wing Lam; Zaoli Jiang; Yung-Chi Cheng
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

2.  Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.

Authors:  Adrienne C Scheck; Krya Perry; Nicole C Hank; W Dennis Clark
Journal:  BMC Complement Altern Med       Date:  2006-08-16       Impact factor: 3.659

3.  Upregulation of death receptor 5 and activation of caspase 8/3 play a critical role in ergosterol peroxide induced apoptosis in DU 145 prostate cancer cells.

Authors:  Jonghyun Han; Eun Jung Sohn; Bonglee Kim; Sunhee Kim; Gunho Won; Sangwook Yoon; Jihyun Lee; Moon Joon Kim; Hojin Lee; Kyujin Chung; Sung-Hoon Kim
Journal:  Cancer Cell Int       Date:  2014-11-30       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.